Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.38 |
| ▸ | HRH2 | P25021 | 5/20 | 0.38 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907041 | 1.00 | KCNH2 (0.50) | KCNH2KDM4EALDH1A1HRH3HRH2 | |
| SCHEMBL5090602 | 0.88 | KCNH2 (0.65) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2956804 | 0.88 | KCNH2 (0.65) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2968433 | 0.83 | KCNH2 (0.47) | KCNH2HRH3HRH2HRH1MEN1 | |
| SCHEMBL2960614 | 0.82 | KCNH2 (0.53) | KCNH2HRH3HRH2HRH1MEN1 | |
| SCHEMBL5097553 | 0.77 | KCNH2 (0.50) | KCNH2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL2969483 | 0.77 | KCNH2 (0.50) | KCNH2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL2970093 | 0.75 | KCNH2 (0.49) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2970091 | 0.75 | KCNH2 (0.49) | KCNH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5091981 | 0.75 | KCNH2 (0.49) | KCNH2KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | claimed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | claimed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | claimed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | claimed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-7164017-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | ASTRAZENECA AB (SE) | 2006-04-06 | — | — | US | disclosed |
| US-20060052314-A1 | Pharmaceutical combination | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | disclosed |
| US-20050119259-A1 | Synergistic mixture of anticoagulant and antiarrhythmia agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| EP-1503783-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003092720-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | KCNH2 9/4885KDM4E 4163/4885ALDH1A1 321/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | KCNH2 11/4885KDM4E 3938/4885ALDH1A1 557/4885 |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885KDM4E 4083/4885ALDH1A1 539/4885 |
| US-20060052314-A1 | Pharmaceutical combination | F2, TNNT2, WFS1 | KCNH2 847/4885KDM4E 3871/4885ALDH1A1 1463/4885 |
| US-20050119259-A1 | Synergistic mixture of anticoagulant and antiarrhythmia agents | KCNH1, VKORC1, VKORC1L1 | KCNH2 50/4885KDM4E 4251/4885ALDH1A1 865/4885 |
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | O60361, KCNH1, WNT3A | KCNH2 47/4885KDM4E 3757/4885ALDH1A1 310/4885 |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KCNH2 8/4885KDM4E 4083/4885ALDH1A1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.